We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Organizations conducting clinical trials will no longer have to submit routine GCP compliance reports that have been used to establish inspections with the UK’s Medicines and Healthcare products Regulatory Agency. Read More
The FDA has accepted Sanofi’s application for expedited review of its once-daily, fixed-dose combination of insulin glargine and GLP-1 receptor agonist lixisenatide for Type 2 diabetes. Read More